Basilea Pharmaceutica Ltd said its has signed a contract with the US Biomedical Advanced Research and Development Authority (BARDA) to co-develop a monosulfactam antibiotic for multidrug-resistant Gram negative bacteria. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
